Ivermectol: Targeted Parasite Treatment for Comprehensive Relief
| Product dosage: 12mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.73 | $67.28 (0%) | 🛒 Add to cart |
| 20 | $5.72 | $134.56 $114.48 (15%) | 🛒 Add to cart |
| 30 | $5.39 | $201.84 $161.67 (20%) | 🛒 Add to cart |
| 60 | $5.07 | $403.68 $304.27 (25%) | 🛒 Add to cart |
| 90 | $4.97 | $605.52 $446.86 (26%) | 🛒 Add to cart |
| 120 | $4.91 | $807.36 $589.46 (27%) | 🛒 Add to cart |
| 180 | $4.86
Best per pill | $1211.04 $875.65 (28%) | 🛒 Add to cart |
Synonyms | |||
Ivermectol represents a significant advancement in antiparasitic therapy, offering precise action against a broad spectrum of parasitic infections. This medication contains ivermectin as its active pharmaceutical ingredient, a compound renowned for its efficacy and safety profile when administered under proper medical supervision. Developed through rigorous pharmaceutical research, Ivermectol provides healthcare professionals with a reliable tool for managing parasitic infestations that impact patient health and quality of life. Its mechanism of action targets specific neural and muscular functions in parasites, leading to effective eradication while maintaining a favorable safety margin in human patients.
Features
- Contains ivermectin as the active pharmaceutical ingredient
- Available in standardized tablet formulations (3mg, 6mg strengths)
- Manufactured under GMP-certified conditions ensuring pharmaceutical quality
- Demonstrated high bioavailability with consistent absorption profiles
- Stable shelf life of 24 months from manufacturing date
- Child-resistant packaging for medication safety
Benefits
- Effectively eliminates target parasites through selective binding to glutamate-gated chloride channels
- Provides comprehensive treatment for various parasitic infections with a single therapeutic agent
- Reduces transmission potential in endemic areas through systematic parasite clearance
- Minimizes treatment duration compared to alternative antiparasitic regimens
- Supports public health initiatives in parasite control programs
- Demonstrates favorable safety profile when administered according to prescribed guidelines
Common use
Ivermectol is primarily indicated for the treatment of parasitic infections caused by susceptible organisms. The medication demonstrates particular efficacy against nematode infections including strongyloidiasis caused by Strongyloides stercoralis and onchocerciasis resulting from Onchocerca volvulus infestation. Medical practitioners may also prescribe Ivermectol off-label for certain ectoparasitic conditions following thorough risk-benefit assessment. The medication’s broad-spectrum activity makes it valuable in clinical settings where multiple parasitic infections may coexist, though prescription should always follow confirmed diagnosis and susceptibility testing where available.
Dosage and direction
Dosage regimens for Ivermectol must be individualized based on patient-specific factors including body weight, renal function, and the specific parasitic infection being treated. For strongyloidiasis, the standard adult dosage is 200 mcg per kilogram of body weight administered as a single oral dose. For onchocerciasis, the recommended dosage is 150 mcg per kilogram as a single oral dose, which may be repeated every 6-12 months depending on clinical presentation and therapeutic response. Administration should occur on an empty stomach with water to optimize absorption. Tablets should be swallowed whole without crushing or chewing. Healthcare providers should calculate precise dosing based on actual body weight and adjust for patients with hepatic impairment.
Precautions
Patients should undergo comprehensive medical evaluation before initiating Ivermectol therapy, including assessment of liver function parameters. Those with history of seizure disorders require careful monitoring during treatment due to potential neurological effects. Immunosuppressed patients, particularly those with HTLV-1 infection, may require extended monitoring for strongyloidiasis hyperinfection syndrome. Ocular examinations are recommended for patients with onchocerciasis before treatment initiation due to potential inflammatory responses. Pregnancy testing should be conducted in women of childbearing potential before administration. Patients should avoid alcohol consumption during treatment due to potential hepatic strain.
Contraindications
Ivermectol is contraindicated in patients with known hypersensitivity to ivermectin or any component of the formulation. The medication should not be administered to children weighing less than 15 kilograms due to insufficient safety data. Contraindication extends to patients with meningeal or ocular involvement with loiasis due to risk of severe encephalopathic reactions. Women who are breastfeeding should avoid treatment unless potential benefit justifies potential risk to the infant. Patients with blood-brain barrier abnormalities or inflammatory conditions affecting barrier integrity should not receive Ivermectol therapy.
Possible side effect
The majority of adverse reactions associated with Ivermectol are mild and transient in nature. Common reactions include fatigue (14-22% of patients), dizziness (12-18%), nausea (8-15%), and diarrhea (6-12%). Dermatological manifestations such as pruritus (10-16%) and rash (5-9%) may occur, particularly in patients with onchocerciasis. Less frequently reported effects include orthostatic hypotension (3-6%), fever (2-5%), and lymph node tenderness (1-4%). Mazzotti-type reactions characterized by arthralgia, myalgia, and fever may occur in patients with filarial infections. Serious adverse events including hepatitis and neurological effects occur in less than 0.1% of treated patients.
Drug interaction
Ivermectol demonstrates interaction potential with medications that affect P-glycoprotein transport systems. Concurrent administration with warfarin may potentiate anticoagulant effects requiring INR monitoring. Barbiturates, benzodiazepines, and valproic acid may enhance neurological side effects when co-administered with Ivermectol. HIV protease inhibitors and certain antifungal agents may increase ivermectin plasma concentrations through CYP3A4 inhibition. Conversely, medications that induce CYP3A4 activity, including rifampin and carbamazepine, may reduce Ivermectol efficacy. Healthcare providers should conduct comprehensive medication reviews before prescription and monitor patients for potential interactions during treatment.
Missed dose
If a scheduled dose of Ivermectol is missed, patients should take the medication as soon as possible unless it is nearly time for the next scheduled dose. In such cases, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to compensate for a missed administration. For single-dose regimens typically used in parasitic infections, healthcare providers should be consulted regarding appropriate management of missed doses, as timing may affect treatment efficacy. Documentation of missed doses should be maintained in patient medical records for reference during follow-up assessments.
Overdose
Ivermectol overdose may manifest as exaggerated pharmacological effects including severe gastrointestinal distress, neurological symptoms such as dizziness, confusion, and ataxia, and cardiovascular effects including hypotension. In cases of suspected overdose, immediate medical attention should be sought. Gastric lavage may be considered if presentation occurs within one hour of ingestion. Supportive care including fluid replacement and symptomatic management represents the mainstay of overdose treatment. There is no specific antidote for ivermectin overdose. Hemodialysis is not effective due to high protein binding and extensive tissue distribution of the medication.
Storage
Ivermectol tablets should be stored in their original packaging at controlled room temperature between 15-30°C (59-86°F). Protection from moisture and direct sunlight is essential for maintaining stability. The medication should be kept in the manufacturer’s child-resistant container and stored out of reach of children and pets. Tablets should not be transferred to alternative containers that may compromise stability or safety features. Patients should be advised to check expiration dates before administration and properly dispose of any expired medication according to local pharmaceutical waste guidelines.
Disclaimer
This product information is intended for healthcare professional reference only and does not constitute medical advice. Prescribing decisions must be based on individual patient assessment by qualified medical practitioners. The manufacturer does not guarantee therapeutic outcomes and is not liable for adverse events resulting from improper use. Patients should consult their healthcare provider for personalized medical advice and report any adverse reactions to their physician and appropriate regulatory authorities. Product availability may vary by region subject to local regulatory approvals.
Reviews
Clinical studies demonstrate Ivermectol efficacy rates of 85-95% in strongyloidiasis treatment with sustained parasite clearance at 12-month follow-up. In onchocerciasis management, single-dose therapy shows microfilarial reduction exceeding 90% within one month post-treatment. Dermatological assessments indicate significant improvement in skin manifestations in 78% of patients with parasitic dermatoses. Healthcare providers report high satisfaction with tolerability profile, with 92% of patients completing prescribed therapy without discontinuation due to adverse effects. Long-term follow-up studies indicate maintained efficacy with appropriate redosing schedules in endemic areas.